NuMedii
Private company
NUMEDII
NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of human, biological, pharmacological and clinical data points that the company has normalized and annotated. The company integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases.
Founded
2008
2008
Status
Private company
Private company
Geography
United States of America based
United States of America based
Funding
$5.500 M
$5.500 M
Website
http://numedii.com/
http://numedii.com/
Patents
1
1
Research papers
14
14
Business model
- Operations Service
Therapeutic focus
- Rare Diseases
Data type used for modelling
- EHRs/lab notebooks/databases (structured data mining)
- Network biology analysis (omics)
- Publications / patents (unstructured data mining)
Product type
- Small molecules
Research focus
- Biology research (Target identification/validation)
- Drug Repurposing
Investing history
| 2015 | Series A | 2.0 |
| 2013 | Series A | 3.5 |
Press releases
No mentions found
Posts Mentioning This Company
Products
No products posted yet
Services
No services posted yet
Clinical Trials
No clinical trials found
Patents/applications
- WO2014165823 (from 2014-10-09), Nadolol formulations for use in the treatment of inflammatory bowel disorders
Publications (PubMed)
No publications found
Assets (therapeutic products)
No assets found
| Year | Partner | Focus | Amount of Deal |
|---|---|---|---|
| 2016
(2016, Jan. 1) |
Astellas | Drug Repurposing | -- |
| 2017
(2017, Jan. 1) |
Aptalis | discover and develop new methods of treatment for certain gastrointestinal disorders and cystic fibrosis | -- |
